NCT07188558View on ClinicalTrials.gov

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

December 31, 2029

Study Completion Date

January 31, 2032

Conditions
Large B-cell LymphomaLymphoma, B-CellRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin LymphomaNon-Hodgkin Lymphoma Refractory/ RelapsedDiffuse Large B Cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma Relapsed
Interventions
BIOLOGICAL

rondecabtagene autoleucel

An autologous, dual-targeting CD19/20 CAR T-cell candidate.

BIOLOGICAL

axicabtagene ciloleucel

An autologous CD19 CAR T-cell therapy

BIOLOGICAL

lisocabtagene maraleucel

An autologous CD19 CAR T-cell therapy

Sponsors
All Listed Sponsors
lead

Lyell Immunopharma, Inc.

INDUSTRY